Showing results (171-180 of 223) with videos related to

Sort By:
Pageof 23
JCO Precision Oncology|February 12, 2025
Cancer Susceptibility Gene Testing in Patients With Pancreatic Ductal Adenocarcinoma: Implementation in a Cancer Center Oncology ClinicHassan Sinan, Dea Cunningham, Emy Abou Sleiman, et al.
Cancer Research Communications|August 30, 2023
Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic CancerH Catherine Wilbur, Jennifer N Durham, Su Jin Lim, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 6, 2016
Ex Vivo Perfusion Treatment of Infection in Human Donor LungsD Nakajima, M Cypel, R Bonato, et al.
Cancer Chemotherapy and Pharmacology|June 22, 2022
A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignanciesWen Wee Ma, Jenny J Li, Nilofer S Azad, et al.
JCO Precision Oncology|June 8, 2022
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune SignaturesKabir Mody, Prerna Jain, Sherif M El-Refai, et al.
Oncotarget|April 29, 2017
Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancerMark Yarchoan, Melinda C Myzak, Burles A Johnson, et al.
Clinical and Translational Science|August 2, 2020
A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic CancerAdrian G Murphy, Marianna Zahurak, Mirat Shah, et al.
Cancers|June 2, 2021
Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in OncologyJoeri A J Douma, Laurien M Buffart, Ramy Sedhom, et al.
Clinical and Translational Science|April 3, 2021
A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotypeMarina Baretti, Enusha Karunasena, Marianna Zahurak, et al.
Biorxiv : the Preprint Server for Biology|August 7, 2023
ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1Jordina Rincon-Torroella, Marco Dal Molin, Brian Mog, et al.
Pageof 23